Research reveals a substrate promiscuous P450 macrocyclase, indicating potential for diverse macrocyclic peptides in pharmaceuticals.
Our findings establish a substrate promiscuous atropopeptide-modifying P450 macrocyclase as a versatile biocatalyst for the biosynthesis of bioactive, C–C or C–N biaryl-bridged macrocyclic peptides with antiviral and anti-inflammatory properties.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: